Lung Cancer

The next portion of Dr. Leighl's "Highlights of Lung Cancer from 2012" webinar focused on exciting research presented at ASCO 2012 and very recently published on the potential efficacy of a new class of targeted therapy, called MEK inhibitors, for the large subset of patients who have a KRAS mutation.

Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.

[powerpress]

Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years. 

[powerpress]

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

[powerpress]

Drs. Ross Camidge and Corey Langer offer their insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

[powerpress]

Dr. Leighl, lung cancer expert from Princess Margaret Hospital in Toronto, continued her summary of the leading highlights in lung cancer from 2012 with coverage of new information on XALKORI for patients with either an ALK rearrangement or the newly identified ROS-1 rearrangement.  

Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Here is the first of the awaited podcasts from Dr. Natasha Leighl's presentation on "Highlights in Lung Cancer from 2012".  Dr.

Dr. Alan Sandler from OHSU describes how acquired resistance to targeted therapies in lung cancer is similar to what is seen with chemo and comments on how he manages patients demonstrating gradual acquired resistance in advanced lung cancer.

[powerpress]

Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]